Premium
Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin‐12p70 and Early Secretory Antigen Target‐6 fusion protein
Author(s) -
Deng Yihao,
Bao Lang,
Yang Xiaoling
Publication year - 2011
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.2011.00376.x
Subject(s) - esat 6 , immunogenicity , mycobacterium bovis , mycobacterium tuberculosis , biology , microbiology and biotechnology , immune system , fusion protein , antigen , tuberculosis , virology , mycobacterium , immunity , recombinant dna , tuberculosis vaccines , immunology , medicine , bacteria , gene , biochemistry , genetics , pathology
ESAT‐6 protein of Mycobacterium tuberculosis is absent in Mycobacterium bovis BCG and Mycobacterium microti and has been demonstrated to stimulate strong cell‐mediated immunity. IL‐12 can play crucial roles in regulating IFN‐γ production and Th1 effectors production. In this study, we constructed three rBCG vaccines that could express proteins of human IL‐12p70 and/or ESAT‐6 and evaluated their immunogenicity and protective efficacy in mice. Our experiments illustrated that the rBCG‐IE (expressing a fusion protein of human IL‐12p70 and ESAT‐6) was capable of inducing stronger Th1 type cell‐mediated immune responses than conventional BCG, or rBCG‐I (expressing human IL‐12p70), or rBCG‐E (expressing ESAT‐6). However, the results of protective experiments showed that rBCG‐IE could only confer similar and even lower protective efficacy against M. tuberculosis H37Rv infection compared with BCG vaccine.